Patents by Inventor Paul Tardi

Paul Tardi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ASSAYS AND METHODS FOR SELECTING A TREATMENT REGIMEN FOR A SUBJECT WITH LEUKEMIA
    Publication number: 20230279503
    Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
    Type: Application
    Filed: May 12, 2023
    Publication date: September 7, 2023
    Inventors: Max GORDON, Paul TARDI, Jeffrey TYNER, Lawrence MAYER
  • Assays and methods for selecting a treatment regimen for a subject with leukemia
    Patent number: 11746386
    Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: September 5, 2023
    Assignees: CELATOR PHARMACEUTICALS, INC., OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Max Gordon, Paul Tardi, Jeffrey Tyner, Lawrence Mayer
  • METHOD OF LYOPHILIZING LIPOSOMES
    Publication number: 20230172855
    Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.
    Type: Application
    Filed: July 13, 2022
    Publication date: June 8, 2023
    Applicant: Celalor Pharmaceuticals, Inc.
    Inventors: Donna CABRAL-LILLY, Lawrence MAYER, Paul TARDI, David WATKINS, Yi ZENG
  • LIPOSOMAL FORMULATIONS OF BCL INHIBITORS
    Publication number: 20230059528
    Abstract: Provided herein are liposomes comprising B-cell lymphoma (Bcl) protein inhibitors, compositions comprising such liposomes, and methods using such formulations for treating hyperproliferative disorders.
    Type: Application
    Filed: July 15, 2022
    Publication date: February 23, 2023
    Applicant: Celator Pharmaceuticals, Inc.
    Inventors: Paul TARDI, Leon Wan, Shyam Madhusudan Garg, Jun Gao, Philippe Legros
  • Nanoparticle delivery systems
    Patent number: 11413253
    Abstract: Nanoparticle compositions described herein comprise combinations of prodrugs of therapeutic agents that achieve enhanced therapeutic effects as compared to those observed when combinations of free forms of these therapeutic agents are administered.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: August 16, 2022
    Assignee: Celator Pharmaceuticals, Inc.
    Inventors: Leon Wan, Winnie Lui, Paul Tardi, Lawrence Mayer
  • ASSAYS AND METHODS FOR SELECTING A TREATMENT REGIMEN FOR A SUBJECT WITH LEUKEMIA
    Publication number: 20210246512
    Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
    Type: Application
    Filed: February 11, 2021
    Publication date: August 12, 2021
    Applicants: Celator Pharmaceuticals, Inc., Oregon Health & Science University
    Inventors: Max GORDON, Paul TARDI, Jeffrey TYNER, Lawrence MAYER
  • METHOD OF LYOPHILIZING LIPOSOMES
    Publication number: 20210169803
    Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.
    Type: Application
    Filed: November 13, 2020
    Publication date: June 10, 2021
    Applicant: Celator Pharmaceuticals, Inc.
    Inventors: Donna CABRAL-LILLY, Lawrence MAYER, Paul TARDI, David WATKINS, Yi ZENG
  • NANOPARTICLE DELIVERY SYSTEMS
    Publication number: 20210052508
    Abstract: Nanoparticle compositions described herein comprise combinations of prodrugs of therapeutic agents that achieve enhanced therapeutic effects as compared to those observed when combinations of free forms of these therapeutic agents are administered.
    Type: Application
    Filed: September 4, 2020
    Publication date: February 25, 2021
    Applicant: Celator Pharmaceuticals, Inc.
    Inventors: Leon WAN, Winnie LUI, Paul TARDI, Lawrence MAYER
  • Assays and methods for selecting a treatment regimen for a subject with leukemia
    Patent number: 10927418
    Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: February 23, 2021
    Assignees: Celator Pharmaceuticals, Inc., Oreoon Health & Science University
    Inventors: Max Gordon, Paul Tardi, Jeffrey Tyner, Lawrence Mayer
  • Method of lyophilizing liposomes
    Patent number: 10835492
    Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: November 17, 2020
    Assignee: CELATOR PHARMACEUTICALS, INC.
    Inventors: Donna Cabral-Lilly, Lawrence Mayer, Paul Tardi, David Watkins, Yi Zeng
  • Compositions for delivery of drug combinations
    Patent number: 10722464
    Abstract: Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: July 28, 2020
    Assignee: Celator Pharmaceuticals, Inc.
    Inventors: Paul Tardi, Troy Harasym, Murray Webb, Clifford Shew, Andrew Janoff, Lawrence Mayer, Marcel Bally
  • NANOPARTICLE DELIVERY SYSTEMS
    Publication number: 20190209484
    Abstract: Nanoparticle compositions described herein comprise combinations of prodrugs of therapeutic agents that achieve enhanced therapeutic effects as compared to those observed when combinations of free forms of these therapeutic agents are administered.
    Type: Application
    Filed: March 15, 2019
    Publication date: July 11, 2019
    Applicant: CELATOR PHARMACEUTICALS, INC.
    Inventors: Leon WAN, Winnie LUI, Paul TARDI, Lawrence MAYER
  • Nanoparticle delivery systems
    Patent number: 10285951
    Abstract: Nanoparticle compositions described herein comprise combinations of prodrugs of therapeutic agents that achieve enhanced therapeutic effects as compared to those observed when combinations of free forms of these therapeutic agents are administered.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: May 14, 2019
    Assignee: CELATOR PHARMACEUTICALS, INC.
    Inventors: Leon Wan, Winnie Lui, Paul Tardi, Lawrence Mayer
  • METHOD OF LYOPHILIZING LIPOSOMES
    Publication number: 20190070112
    Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.
    Type: Application
    Filed: November 5, 2018
    Publication date: March 7, 2019
    Applicant: CELATOR PHARMACEUTICALS INC.
    Inventors: Donna CABRAL-LILLY, Lawrence MAYER, Paul TARDI, David WATKINS, Yi ZENG
  • Method of lyophilizing liposomes
    Patent number: 10166184
    Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: January 1, 2019
    Assignee: CELATOR PHARMACEUTICALS INC.
    Inventors: Donna Cabral-Lilly, Lawrence Mayer, Paul Tardi, David Watkins, Yi Zeng
  • COMPOSITIONS FOR DELIVERY OF DRUG COMBINATIONS
    Publication number: 20180338917
    Abstract: Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered.
    Type: Application
    Filed: July 27, 2018
    Publication date: November 29, 2018
    Inventors: Paul TARDI, Troy HARASYM, Murray WEBB, Clifford SHEW, Andrew JANOFF, Lawrence MAYER, Marcel BALLY
  • ASSAYS AND METHODS FOR SELECTING A TREATMENT REGIMEN FOR A SUBJECT WITH LEUKEMIA
    Publication number: 20180327854
    Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
    Type: Application
    Filed: November 10, 2016
    Publication date: November 15, 2018
    Applicants: Celator Pharmaceuticals Inc., OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Max GORDON, Paul TARDI, Jeffrey TYNER, Lawrence MAYER
  • COMBINATION METHODS AND COMPOSITIONS
    Publication number: 20180271787
    Abstract: Compositions which comprise a liposomal camptothecin and optionally liposomal fluoropyrimidine and a targeted antitumor agent are useful in achieving enhanced therapeutic effects when combinations of these agents are administered.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 27, 2018
    Applicant: CELATOR PHARMACEUTICALS, INC.
    Inventors: Paul TARDI, Lawrence MAYER, David BERMUDES
  • Compositions for delivery of drug combinations
    Patent number: 10058507
    Abstract: Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: August 28, 2018
    Assignee: CELATOR PHARMACEUTICALS, INC.
    Inventors: Paul Tardi, Troy Harasym, Murray Webb, Clifford Shew, Andrew Janoff, Lawrence Mayer, Marcel Bally
  • IMPROVED NANOPARTICLE DELIVERY SYSTEMS
    Publication number: 20180207104
    Abstract: Nanopaiticle compositions described herein comprise combinations of prodrugs of therapeutic agents that achieve enhanced therapeutic effects as compared to those observed when combinations of free forms of these therapeutic agents are administered.
    Type: Application
    Filed: July 14, 2016
    Publication date: July 26, 2018
    Applicant: CELATOR PHARMACEUTICALS, INC.
    Inventors: Leon WAN, Winnie LUI, Paul TARDI, Lawrence MAYER